PT1151102E - Composicoes de leptina glicosilada e metodos afins - Google Patents

Composicoes de leptina glicosilada e metodos afins

Info

Publication number
PT1151102E
PT1151102E PT00911784T PT00911784T PT1151102E PT 1151102 E PT1151102 E PT 1151102E PT 00911784 T PT00911784 T PT 00911784T PT 00911784 T PT00911784 T PT 00911784T PT 1151102 E PT1151102 E PT 1151102E
Authority
PT
Portugal
Prior art keywords
proteins
compositions
glycosylated
leptin
methods
Prior art date
Application number
PT00911784T
Other languages
English (en)
Portuguese (pt)
Inventor
Frances H Martin
Steven G Elliott
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT1151102E publication Critical patent/PT1151102E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT00911784T 1999-02-12 2000-02-11 Composicoes de leptina glicosilada e metodos afins PT1151102E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24967599A 1999-02-12 1999-02-12

Publications (1)

Publication Number Publication Date
PT1151102E true PT1151102E (pt) 2006-07-31

Family

ID=22944511

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00911784T PT1151102E (pt) 1999-02-12 2000-02-11 Composicoes de leptina glicosilada e metodos afins

Country Status (11)

Country Link
EP (1) EP1151102B1 (https=)
JP (1) JP4841037B2 (https=)
AT (1) ATE323766T1 (https=)
AU (1) AU781460B2 (https=)
CA (1) CA2359840C (https=)
CY (1) CY1107470T1 (https=)
DE (1) DE60027409T2 (https=)
DK (1) DK1151102T3 (https=)
ES (1) ES2257287T3 (https=)
PT (1) PT1151102E (https=)
WO (1) WO2000047741A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2003020303A1 (en) * 2001-08-29 2003-03-13 The University Of Buckingham Use of leptin for infant with low birth weight for prevention of obesity
PT2219031E (pt) * 2001-10-22 2013-05-17 Amgen Inc Uso de leptina para tratamento de lipoatrofia humana e método para determinar predisposição ao referido tratamento
US7094579B2 (en) * 2002-02-13 2006-08-22 Xoma Technology Ltd. Eukaryotic signal sequences for prokaryotic expression
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
WO2005030963A1 (en) 2003-09-26 2005-04-07 Applied Research Systems Ars Holding N.V. Leader sequences for use in production of proteins
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US8642543B2 (en) 2005-09-07 2014-02-04 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2008067599A1 (en) * 2006-12-04 2008-06-12 Apollo Life Sciences Limited Isolated leptin and adiponectin molecules and chimeric molecules thereof
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
JP2009126856A (ja) * 2007-11-28 2009-06-11 Fancl Corp 血中中性脂肪上昇抑制剤
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
SI3074033T1 (sl) 2013-11-26 2019-03-29 The Children's Medical Center Corporation Spojine za zdravljenje debelosti in postopki njihove uporabe
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
CA3036551A1 (en) 2016-09-12 2018-03-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
CN1057534C (zh) * 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
AU4766596A (en) * 1995-01-31 1996-08-21 Eli Lilly And Company Ob gene product antibodies
WO1997018833A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
JPH09176198A (ja) * 1995-12-28 1997-07-08 Kikkoman Corp 抗肥満タンパク質モノクローナル抗体及びハイブリドーマ
JP2000505791A (ja) * 1996-01-25 2000-05-16 イーライ・リリー・アンド・カンパニー 肥満症タンパク質類似体化合物およびその製剤
EP0827750A3 (en) * 1996-08-23 2002-11-20 Eli Lilly And Company Obesity protein formulations
WO1999023115A1 (en) * 1997-10-31 1999-05-14 Eli Lilly And Company Glycosylated obesity protein analogs
JP4199421B2 (ja) * 1998-08-10 2008-12-17 アムジエン・インコーポレーテツド デキストラン−レプチン結合体、医薬組成物および関連方法
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility

Also Published As

Publication number Publication date
DE60027409T2 (de) 2007-04-12
DE60027409D1 (de) 2006-05-24
CA2359840C (en) 2012-10-23
WO2000047741A1 (en) 2000-08-17
ATE323766T1 (de) 2006-05-15
AU781460B2 (en) 2005-05-26
EP1151102B1 (en) 2006-04-19
AU3362300A (en) 2000-08-29
DK1151102T3 (da) 2006-05-29
CY1107470T1 (el) 2012-12-19
JP2002536018A (ja) 2002-10-29
ES2257287T3 (es) 2006-08-01
CA2359840A1 (en) 2000-08-17
JP4841037B2 (ja) 2011-12-21
EP1151102A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
PT1151102E (pt) Composicoes de leptina glicosilada e metodos afins
AU2001254624A1 (en) Human coagulation factor vii variants
BRPI0410164A (pt) composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
DK1904635T3 (da) Glycosyleret IL-7, fremstilling og anvendelser
WO2003059934A3 (en) Albumin fusion proteins
WO2002060955A3 (en) Modified antibodies and methods of use
WO2000034317A3 (en) Method for reducing immunogenicity of proteins
EP2330127A3 (en) Kallikrein-inhibiting Kunitz Domain proteins and nucleic acids encoding the same
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
EP2277889A3 (en) Fusion proteins of albumin and interferon beta
DK0733067T3 (da) N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
HUP0001153A2 (hu) Kémiailag módosított polipeptidek, eljárás ezek előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE337014T1 (de) Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen
EP0797999A3 (en) Formulations of obesity protein
FI20075338A7 (fi) gp350/220:n ei silmukoivia muutoksia
ES2168361T3 (es) Secuencias de adn para metaloproteasas de la matriz, su preparacion y empleo.
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
ATE313562T1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
UA100967C2 (ru) Конъюгаты нейбластина с полимерами и способы их применения
WO2003008449A8 (en) Ntb-a, a surface molecule involved in natural killer cells activity
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
AUPM772494A0 (en) Improvements in production of proteins in host cells